United Kingdom Toll/International: +44 20 3936 2999įor those unable to listen to the call live, a replay will be available on the PureTech website.Ĭommenting on PureTech’s half-yearly results, Daphne Zohar, Founder and Chief Executive Officer of PureTech, said: A live webcast and presentation slides will be available on the investors section of PureTech’s website under the Events and Presentations tab. Members of the PureTech management team will host a conference call at 9:00am EDT / 2:00pm BST today, August 25, 2022, to discuss these results. The following information will be filed on Form 6-K with the United States Securities and Exchange Commission (the “SEC”) and is also available at. PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its half-yearly results for the six months ended June 30, 2022. Significant advancement of PureTech’s Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platformĮxcellent progress across the Founded Entities, including Karuna’s positive topline Phase 3 results for KarXT in schizophrenia, Akili’s Nasdaq listing and Gelesis’ commercial progress with Plenity ® 4 in the post-period, and four clinical data publications across Founded EntitiesĬompany to host a webcast and conference call today at 9:00am EDT / 2:00pm BST Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million 1 and Consolidated Cash and Cash Equivalents of $365.9 million 2 as of June 30, 2022, excluding up to $115.4 million added post-period 3 Operational runway extended into Q1 2026
0 kommentar(er)
